These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36831820)

  • 1. Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review.
    Sanchez Alonso P; De La Casa-Fages B; Alonso-Cánovas A; Martínez-Castrillo JC
    Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
    Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
    Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
    JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
    ; Bergmans B; Bourgeois P; Cras P; Dethy S; De Klippel N; Franco G; Garraux G; Geens K; Jacquerye P; Jeanjean A; Supiot F; Van der Linden C; Krygier C
    Acta Neurol Belg; 2023 Jun; 123(3):939-947. PubMed ID: 36201116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
    Morales-Casado MI; García-Meléndez DD; Diezma-Martín A; López-Ariztegui N
    Rev Neurol; 2023 Oct; 77(S03):S1-S7. PubMed ID: 37882094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
    Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
    Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
    Stocchi F; Vacca L; Grassini P; Tomino C; Caminiti G; Casali M; D'Antoni V; Volterrani M; Torti M
    Eur J Neurol; 2021 Jan; 28(1):349-354. PubMed ID: 32961619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
    Rizzone MG; Mancini F; Artusi CA; Balestrino R; Bonvegna S; Fabbri M; Imbalzano G; Montanaro E; Romagnolo A; Zibetti M; Lopiano L
    Neurol Sci; 2022 May; 43(5):3187-3193. PubMed ID: 34982297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.